A prostate stem cell antigen‐derived peptide immunogenic in HLA‐A24− prostate cancer patients
- 2 February 2004
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 60 (3) , 205-213
- https://doi.org/10.1002/pros.20038
Abstract
BACKGROUND: We attempted to identify prostate stem cell antigen (PSCA)‐derived peptides immunogenic in HLA‐A24+ prostate cancer patients.METHODS: Peripheral blood mononuclear cells (PBMCs) were stimulated in vitro with each of three different PSCA‐derived peptides, which were prepared based on the HLA‐A24 binding motif, and their peptide‐specific and HLA‐A24‐restricted anti‐tumor responses were examined. Plasma levels of immunoglobulin G (IgG) against PSCA peptides were measured by enzyme‐linked immunosorbent assay (ELISA).RESULTS: Among three PSCA peptides, the PSCA 76–84 peptide most effectively induced peptide‐specific cytotoxic T lymphocytes (CTLs) from PBMCs of HLA‐A24+ prostate cancer patients. Cytotoxicity was dependent on peptide‐specific and CD8+ T cells. The PSCA 76–84 peptide‐stimulated PBMCs showed a significant level of cytotoxicity against prostate cancer cells in an HLA‐A24‐restricted manner. IgG reactive to the PSCA 76–84 peptide was detected in half of patients.CONCLUSIONS: The PSCA 76–84 peptide should be considered for use in clinical trials of immunotherapy for HLA‐A24+ patients.Keywords
This publication has 30 references indexed in Scilit:
- Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2 + patients with hormone-refractory prostate cancerCancer Immunology, Immunotherapy, 2004
- Prostate‐specific antigen‐derived epitopes capable of inducing cellular and humoral responses in HLA‐A24+ prostate cancer patientsThe Prostate, 2003
- Target molecules in specific immunotherapy against prostate cancerInternational Journal of Clinical Oncology, 2003
- Induction of cellular and humoral immune responses to tumor cells and peptides in HLA‐A24 positive hormone‐refractory prostate cancer patients by peptide vaccinationThe Prostate, 2003
- Peptide Vaccination for Patients With Melanoma and Other Types of Cancer Based on Pre-existing Peptide-Specific Cytotoxic T-Lymphocyte Precursors in the PeripheryJournal of Immunotherapy, 2003
- Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patientsInternational Journal of Cancer, 2002
- INDUCTION OF TUMOR SPECIFIC CYTOTOXIC T LYMPHOCYTES IN PROSTATE CANCER USING PROSTATIC ACID PHOSPHATASE DERIVED HLA-A2402 BINDING PEPTIDEJournal of Urology, 2001
- Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancerOncogene, 2000
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived From Prostate-Specific AntigenJNCI Journal of the National Cancer Institute, 1997